Mergers & Acquisitions Sun Pharma Acquires Ranbaxy Laboratories

Editor: Dominik Stephan

Sun Pharmaceutical Industries Ltd plans to acquire Ranbaxy Laboratories Ltd for US$ 4 billion. The combination of Sun Pharma and Ranbaxy creates the fifth-largest specialty generics company in the world and the largest pharmaceutical company in India.

Related Vendors

Sun Pharma Acquires Ranbaxy Laboratories
Sun Pharma Acquires Ranbaxy Laboratories
(Picture: PROCESS)

Mumbai/India -The combined entity will have operations in 65 countries, 47 manufacturing facilities across five continents, and a significant platform of specialty and generic products marketed globally, including 629 ANDAs.

Talking about the acquisition, Managing Director, Sun Pharma, Dilip Shanghvi said, “Ranbaxy has a significant presence in the Indian pharma market and in the US where it offers a broad portfolio of ANDAs and first-to-file opportunities. In high-growth emerging markets, it provides a strong platform, which is highly complementary to Sun Pharma’s strengths. We see tremendous growth opportunities and are excited with the prospects to create lasting value for both our shareholders through a successful combination of our franchises.”

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy.

Unfold for details of your consent

(ID:42651129)